Prosecution Insights
Last updated: July 17, 2026
Application No. 17/421,803

COMBINATION DRUG THERAPIES OF PDE-5 INHIBITORS AND INHALED NITRIC OXIDE

Final Rejection §103§112
Filed
Jul 09, 2021
Priority
Jan 14, 2019 — provisional 62/792,329 +2 more
Examiner
HOWELL, GWYNNETH LINNEA
Art Unit
3785
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Mallinckrodt Pharmaceuticals Ireland Limited
OA Round
6 (Final)
43%
Grant Probability
Moderate
7-8
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 43% of resolved cases
43%
Career Allowance Rate
29 granted / 67 resolved
-26.7% vs TC avg
Strong +80% interview lift
Without
With
+80.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
35 currently pending
Career history
97
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
82.4%
+42.4% vs TC avg
§102
12.1%
-27.9% vs TC avg
§112
3.4%
-36.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 67 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment This office action is in response to amendment filed 04/13/2026. As directed by the amendment, claims 2-11 and 13-24 were canceled, claims 1, 12, and 25-26 were amended, and claims 27-42 were newly added. Thus, claims 1, 12, and 25-42 are presently pending in this application. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 1, 12, and 25-42 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Regarding claim 1 lines 21-22 and claim 12 lines 22-23, the term “wherein the breath level trigger is configured to be more sensitive than the breath slope trigger” is unclear. Both the breath level trigger and breath slope trigger are used to detect breath (specification [0029]). In the specification, [0030] “The breath level trigger detects a breath when a threshold level of pressure (e.g., a threshold negative pressure) is reached upon inspiration.” Furthermore, in specification [0031] “a breath slope trigger detects breath when the slope of a pressure waveform indicates inspiration”. Thus, the breath level and breath slope triggers are doing essentially the same thing in differing ways, to provide more accurate breath detection (specification [0032]). The addition of the “sensitivity” language is unclear in both the claim and specification. The only mention of sensitivity regarding the breath level and breath slope triggers is in specification paragraphs [0033-0034], stating the breath sensitivity control is fixed, adjustable from a range of least to most sensitive, or programmable. The sensitivity of each trigger can be set to different relative levels. However, it is unclear how “sensitivity” is defined or measured within the context of breath level trigger with respect to breath slope trigger. As evidenced above, both the breath level and breath slope triggers are detecting breath, so how is one trigger more sensitive to detecting a breath than the other if the breath is occurring nonetheless? Is there a flow meter with different levels of sensitivity that the breath level and breath slope triggers are associated to trigger? Are their values of sensitivity associated with each trigger that show how one trigger could be more/less sensitive than the other? Thus, the specification fails to provide adequate written description as to how the invention functions. Any remaining claims are rejected as being dependent upon a rejected base claim. Response to Arguments Applicant's arguments filed 04/13/2026 have been fully considered but they are not persuasive. Applicant’s arguments, see pages 7-9 of the remarks, filed 04/13/2026, with respect to the rejection(s) of claim(s) 1, 3-6, 9-11, 23, and 25 under 35 USC 103 have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of 35 USC 112(a) above. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GWYNNETH L HOWELL whose telephone number is (703)756-4742. The examiner can normally be reached 8:30-4:30 M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Tim Stanis can be reached on (571) 272-5139. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GWYNNETH L HOWELL/Examiner, Art Unit 3785 /RACHEL T SIPPEL/Primary Examiner, Art Unit 3785
Read full office action

Prosecution Timeline

Show 7 earlier events
Jul 15, 2025
Response Filed
Sep 08, 2025
Final Rejection mailed — §103, §112
Dec 03, 2025
Request for Continued Examination
Dec 12, 2025
Response after Non-Final Action
Jan 13, 2026
Non-Final Rejection mailed — §103, §112
Apr 13, 2026
Response Filed
Jun 24, 2026
Final Rejection mailed — §103, §112
Jul 15, 2026
Interview Requested

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678578
METHODS AND SYSTEMS FOR AUTOMATED DETECTION OF WATER ACCUMULATION ON VENTILATOR AIRWAY CIRCUITS FROM AIRWAY PRESSURE AND FLOW
2y 7m to grant Granted Jul 14, 2026
Patent 12667688
HEAT AND MOISTURE EXCHANGER FOR PATIENT INTERFACE
4y 7m to grant Granted Jun 30, 2026
Patent 12636525
FACE MASK
4y 2m to grant Granted May 26, 2026
Patent 12636215
WEARABLE SUIT
4y 0m to grant Granted May 26, 2026
Patent 12616638
Gas circuit control system of pneumatic cardiopulmonary resuscitation pressing device
3y 9m to grant Granted May 05, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

7-8
Expected OA Rounds
43%
Grant Probability
99%
With Interview (+80.1%)
3y 9m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 67 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month